BUFFALO, New York and HONG KONG, July 8, 2016 /PRNewswire/ -- Athenex, Inc. announced today that James Hussey has joined the Company as Executive Vice President of Athenex Pharmaceutical Division. In this capacity, Mr. Hussey will be responsible for the execution of the commercial aspects of this business unit including strategy, new products, manufacturing, distribution, sales and marketing.
Mr. Hussey has extensive experience with high potency oncology drugs. Prior to Athenex he was the President of Sagent Pharmaceuticals. Before Sagent, he led numerous pharmaceutical and healthcare companies, as President and CEO of Nanolnk, Inc., President and CEO of NeoPharm Pharmaceuticals, Inc., where he oversaw new formulations of Taxol and Doxorubicin, and Founder, President and CEO of Physicians Quality Care, Inc. Mr. Hussey was also a General Manager of a U.S. Business division of Bristol-Meyers Squibb, the original developer of intravenous Taxol. He holds a B.S. in Pharmacy from Butler University and a MBA from University of Illinois, Chicago.
Mr. Flint Besecker, Athenex Chief Operating & Financial Officer and Board Director commented, "Jim's reputation and his previous experience in pharmaceutical commercialization, marketing and sales are a tremendous addition to Athenex. We are thrilled to have someone with his extensive credentials join the leadership team, and our Board warmly welcomes him."
Mr. James Hussey stated, "I have been incredibly impressed by Athenex's innovative oncology ecosystem, its strong management, and its commitment to improving the lives of cancer patients everywhere. With its strong proprietary pipeline and strategy for growth in the U.S. and China markets, I see Athenex as one of the most exciting technology development companies in healthcare. I am delighted to join the Athenex leadership team and look forward to making a substantial contribution to the company's success."
Mr. Jeffrey Yordon, President of Athenex Pharmaceutical Division commented, "I've worked with Jim in the past and am thrilled that he has joined our leadership team. Jim's extensive experience bringing pharmaceutical products to the global market, including China and the U.S., align well with our innovative technology platform and strategy for global growth. Jim's contributions to our organization will add new products to our proprietary pipeline, allowing us to offer combination therapies complementary to our existing oncology ecosystem. We are excited to have Jim join the Athenex team."
About Athenex, Inc.
Founded in 2003, Athenex is an innovative oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies with a particular emphasis on the China and U.S. markets. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. The Athenex business includes: three portfolios of innovative proprietary products under development, medical technology research innovation centers, product development and regulatory teams and existing manufacturing facilities in China and the U.S. Athenex employees include several hundred dedicated professionals to the mission of improving the lives of cancer patients throughout the world. With a connected ecosystem, including an innovation, development and manufacturing presence concentrated in China and the U.S., Athenex can identify, develop, and deliver unique medical technology across continents and multiple regulatory environments. Athenex has offices throughout the United States and Greater China regions.
For more information about Athenex's portfolio of proprietary products and clinical studies, please visit www.athenex.com.
